54
Participants
Start Date
February 18, 2021
Primary Completion Date
December 2, 2022
Study Completion Date
December 2, 2022
ABI-H0731
Participants will receive ABI-H0731 300 mg tablets orally once daily
ETV
Participants will receive ETV 0.5 mg tablets orally once daily
Peg-IFNα
Participants will receive Peg-IFNα with a starting dose of 180 µg solution by subcutaneous injection once weekly
Beijing Friendship Hospital, Capital Medical University, Beijing
Beijing YouAn Hospital, Capital Medical University, Beijing
Jilin University First Hospital, Changchun
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai
Shanghai Public Health Clinical Center, Shanghai
The Second Xiangya Hospital of Central South University, Changsha
Nanfang Hospital, First Military Medical University, Guangzhou
8th Affiliated Hospital of Guangzhou, Guangzhou
The first affiliated Hospital, College of Zhejiang University, Hangzhou
Lead Sponsor
Assembly Biosciences
INDUSTRY